What type of study is this?

This is a Meta-Analysis study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

Investigate TFF1/ESR1 decoupling as a biomarker for predicting HDAC inhibitor benefits in Luminal B breast cancer.

March 8, 2026Open Access

View Full Paper

Ask AI

Bookmark

Authors

Discovery highlights a clinical prediction for HDAC inhibitor benefit in Luminal B breast cancer, suggesting TFF1/ESR1 ratio use as a biomarker.

Investigate TFF1/ESR1 decoupling as a biomarker for predicting HDAC inhibitor benefits in Luminal B breast cancer.
Utilized single-cell RNA sequencing for discovery in LumB breast cancer samples.
Validated findings through the METABRIC dataset of bulk RNA sequencing.
Analyzed co-expression of DNMT3A and HDAC2 in LumB versus LumA cancer types.
TFF1/ESR1 ratio lower in LumB, indicating decoupled ER function despite higher ESR1 levels.
Identified DNMT3A/HDAC2 coupling as a mechanism for this decoupling.
Clinical predictions made regarding the efficacy of entinostat in specific LumB patient populations.

Eric Robert Lawson (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Discovery highlights a clinical prediction for HDAC inhibitor benefit in Luminal B breast cancer, suggesting TFF1/ESR1 ratio use as a biomarker.